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History and Backdrop
Over the last six decades, an in-group with ideological and financial stakes has been
conducting sub-par research to develop an ostensibly effective clinical intervention:
electroencephalography neurofeedback (EEG-nf). More recently, however, a string of
independent studies featuring increased scientific rigour and tighter experimental controls has
challenged the foundation on which EEG-nf stands. Earlier this year, Brain published one of the
most robust EEG-nf experiments to date (Schabus et al., 2017), which sparked a flurry of
correspondence concerning the therapeutic value of neurofeedback (Fovet et al., 2017; Schabus,
2017); notably, a parallel discussion continues in Lancet Psychiatry (Micoulaud-Franchi and
Fovet, 2016; Thibault and Raz, 2016a; Schönenberg et al., 2017). However, to effectively
interpret the pro and con viewpoints, one must appreciate the peculiar culture surrounding the
field of EEG-nf. The present breezy piece provides little-discussed yet highly-relevant contextual
information often absent from formal papers and technical reports.
EEG-nf thrives in two major arenas: commercial and academic. The commercial branch
includes private practitioners, equipment manufacturers, as well as other corporate and lucrative
aspects of neurofeedback. Most of the research that fuels these commercial ventures comes from
vanity presses and specialty associations, including the Institute for Neurofeedback and Research
(ISNR), the Biofeedback Federation of Europe (BFE), the Association for Applied
Psychophysiology and Biofeedback (AAPB), and the Biofeedback Certification International
Alliance (BCIA), as well as private entities (e.g., EEGInfo.com). These associations publish
everything from magazines for lay audiences to methodological textbooks for practitioners and
research journals that rarely seek referees beyond their clique (e.g., NeuroRegulation). The
leaders of these commercial organizations often have financial and ideological stakes in EEG-nf
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(Thibault and Raz, 2017). Moreover, they frequently promote and offer training for
neurofeedback techniques that rarely receive attention outside the commercial sphere (e.g.,
QEEG, z-score training, LORETA feedback). Thus, these circles rely on research that shies away
from standard scientific thoroughness.
More than a decade ago, in a motion designed to separate themselves from commercial
interests, the European branch of the ISNR split off to create the Society of Applied
Neuroscience (SAN)—a more academic group focused on how EEG-nf works, rather than on
promoting commercial products and services. We were invited to present at SAN’s most recent
meeting in Greece and one of us (RTT) attended. RTT was surprised to hear the SAN president
open the conference with a statement that the society aims to prove that neurofeedback works—a
non-scientific starting point of a troublesome agenda. At the first neurofeedback workshop, a
practitioner asked a volunteer to up-regulate a subset of EEG waves known as the alpha band.
After the practitioner displayed the data demonstrating “successful” up-regulation of alpha, RTT
pointed out an apparent contradiction: the volunteer actually misunderstood the instructions and
was actively attempting to down-regulate, not up-regulate, alpha, but the audience seemed to
neither notice nor care. The next day, when RTT presented on the topic of psychosocial
influences and the need for strong experimental controls, he received a response reflecting an alltoo-common stance in the field: “Why don’t we focus on the more important issues?” (e.g.,
identifying what bandwidth to train or specifying the presumed neurophysiological mechanisms).
Many members of the neurofeedback community adhere to the premise that EEG-nf
alters brain activity and that this neural modulation improves behaviour. However, we have
systematically analysed some of the underlying problems with this tenet and found that
expectation, suggestion, motivation, and other such factors likely drive the observed behavioural
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outcomes (Thibault et al., 2016, 2017). Subsequently, some practitioners have responded to our
critical reports with a string of passionate communications: emails, non-peer-reviewed articles
(e.g., Othmer, 2017), and YouTube videos (e.g., Othmer, 2016). To paraphrase the main point,
albeit specious, that they put forward: “placebo effects alone cannot possibly explain the benefits
of EEG-nf”. But the scientific evidence shows otherwise (Thibault et al., 2015; Raz and Harris,
2016).
Registries and False Positives
While EEG-nf experiments with positive findings abound, the absence of a formal
registry makes it difficult, if not impossible, to identify how many negative findings fail to reach
publication. In a first step to improve this state-of-affairs, Manuel Schabus recently set up an
informal open repository for researchers to post their neurofeedback findings—be they positive
or negative (http://decision.sbg.ac.at/limesurvey/index.php/778671/lang-en). This exciting
development may lead to further, perhaps more formal, platforms to encourage transparent and
rigorous neurofeedback research. Bear in mind, however: positive results can represent veridical
effects or false positives.
The field of EEG-nf remains susceptible to a high proportion of false positives. At least
six characteristics have been identified as predicting a systematic high-risk of false-positives:
small sample sizes, small effect sizes, exploratory analyses, flexible research designs, ideological
or financial interests, and the trendiness of a field (Ioannidis, 2005). Empirically, EEG-nf scores
highly on many of these characteristics. An important next step for the field of neurofeedback,
therefore, would be to pre-register clinical trials (e.g., on platforms such as www.osf.io), in line
with the standard of other clinical domains.
Constructive Ways to Move Forward
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Most scientists would agree that higher-quality studies are long overdue for a field
spanning almost 60 years of research, with over 3,000 publications, and hundreds, if not
thousands, of private practitioners (Thibault and Raz, 2016b). However, unlike standard clinical
researchers, many proponents of neurofeedback seem to undervalue the power of psychosocial
influence and disregard the necessity for proper experimental design and control conditions. A
more robust understanding of the science of placebo factors, alongside an appreciation for the
value of parsimony and falsifiability (e.g., as championed by William of Ockham and Karl
Popper), would surely lead neurofeedback advocates to consider alternative explanations
(Thibault et al., 2017). Instead, proponents of EEG-nf continue to make unsubstantiated claims.
In a recent Letter to the Editor, Fovet et al. (2017) argue that we need “a deeper
exploration of the neural mechanisms and methodological nuances emerging from this
embryonic field—preferably before premature launches of double-blind clinical studies”. And
yet, robust studies have already begun to report neural data from double blind experiments (e.g.,
Schabus et al., 2017; Schönenberg et al., 2017)—precisely the type of studies that would be
necessary to specify what drives the neurophysiological and behavioural outcomes. In earlier
writings, Fovet et al. contradicted themselves by suggesting that “despite [the lack of doubleblind studies], neurofeedback research is not at an embryonic stage…findings from several
single randomised trials and non-randomised studies have supported the clinical efficacy of
EEG-neurofeedback in ADHD” (Micoulaud-Franchi and Fovet, 2016). Such conflicting
statements—arguing that, on the one hand, the field is too nascent for a judgement call while, on
the other hand, sufficient evidence supports the application of EEG-nf—present a conundrum.
Moreover, Fovet et al. further argue that the correlations between EEG regulation and sleep
quality in the Schabus et al. (2014) study are difficult to reduce to placebo mechanisms. Yet,

5

placebo factors such as motivation and effort could conceivably improve both task performance
and sleep quality, thus leading to a systematic correlation between these outcome measures. It
seems that the power and nuance of placebo science eludes many.
Researchers should be able to conduct high-quality research even with financial and
ideological ties. To do so, they must largely remove their partialities from the experimental
process and the interpretation of results; for example, by blinding those who analyse the data and
by weighing alternative explanations (Nuzzo, 2015). Unfortunately, however, such practices
remain rare in EEG-nf research.
Progress in this field requires new research directions. For example, advances in
machine-learning permit us to move beyond the traditional fragmentation of brain activity into
five rigid bandwidths (i.e., alpha, beta, gamma, delta, theta) and to seek more nuanced and
accurate neural signatures of target mental states (e.g., Meir-Hasson et al., 2014). Researchers
further leverage simultaneous recording of EEG and functional magnetic resonance imaging
(fMRI) in an attempt to circumvent the controversies of EEG-nf by training complex electrical
brain patterns that correlate with signal changes in fMRI (Keynan et al., 2016). The jury is still
out on whether or not these procedures can reliably entrain brain and behaviour, but that is a
testable hypothesis—an empirical question—answerable by responsible experimentation.
In sum, ideological and financial interests dominate the field of EEG-nf. This state of
affairs skews common perception with a biased literature that rests on weakly designed
experiments and a systematic high-risk of false positives. Proponents of EEG-nf may continue to
“fix neural pathways” and “regulate emotional networks” while optimistic start-ups look for
better ways to “train the brain”; alas, the legitimacy of EEG-nf is losing buoyancy in a pool
quickly filling with defiant data. If the community of neurofeedback practitioners continues to
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uncritically sing the praises of their intervention instead of providing solid scientific evidence to
support their claims, the field, if it hasn't already, risks reducing to a boondoggle.
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